ArticleVirchows Archiv : an international journal of pathology2025
Biphasic (squamoid) papillary renal cell carcinoma: a distinct molecular and morphologic subtype within the PRCC spectrum.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biphasic (squamoid) papillary renal cell carcinoma (BPRCC) is a recently recognized and rare variant of renal cell carcinoma, defined by biphasic morphology and distinct immunophenotypic features. Previously considered a subtype of classic papillary RCC, its clinicopathologic and molecular characteristics remain underexplored. We analyzed ten BPRCC cases for histologic, immunophenotypic, molecular, and clinical features. The cohort included seven men and three women (median age = 48 years), with tumors measuring 25-45 mm, all staged as pT1. No disease progression or cancer-related deaths were observed over a median follow-up of 55 months. Histologically, all tumors showed biphasic architecture with variable proportions of large eosinophilic squamoid and smaller basophilic cells. One tumor demonstrated focal rhabdoid-like features. Immunostains were diffusely positive for PAX8, CK7, AMACR, and Claudin4. The two cell populations showed differential expression of Cyclin D1, AMACR, HMWCK (K903), E-cadherin, and Ki-67. All tumors were negative for GATA3, p63, and CAIX (focal in 2 cases), and showed intact p53, RB1, and mismatch repair proteins. FISH confirmed trisomy 7 and 17 in all tumors. Targeted NGS revealed MET amplification (2 cases), MET mutation (1 case), NOTCH1 mutations (9 cases), and alterations in MAP2K2, FGFR4, DDR pathway genes (e.g., PMS2, CDK12R44W, RAD51C/D), and chromatin remodeling genes (EZH2, ARID1A). These findings support BPRCC as a distinct subtype of papillary RCC with consistent biphasic morphology, immunophenotypic divergence, and a unique molecular profile enriched for NOTCH, MAPK, and DDR pathway alterations.
Indexed as
Identifiers
41006900What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.